Abstracts Archive - Page 2380 of 2607 - ACR Meeting Abstracts

Abstract Number: 779 • 2013 ACR/ARHP Annual Meeting
Low Cardiovascular Mortality Among Early Rheumatoid Arthritis Patients — A Nationwide Register Study 2000—2008
Anne M. Kerola¹, Tuomo Nieminen², Lauri J. Virta³, Hannu Kautiainen⁴, Kari Puolakka⁵, Tuomas Kerola⁶, Timo Pohjolainen⁷ and Markku J. Kauppi⁶, ¹Medical School, University of Helsinki, Helsinki, Finland, ²Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland, ³Research Department, the Social Insurance Institution, Turku, Finland, ⁴Unit of Primary Health Care, Helsinki University Central Hospital, Helsinki, Finland, ⁵Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland, ⁶Department of Internal Medicine, Päijät-Häme Central Hospital, Lahti, Finland, ⁷ORTON Rehabilitation Centre, ORTON Foundation, Helsinki, Finland
Background/Purpose: Increased cardiovascular (CV) mortality in established rheumatoid arthritis (RA) is a widely accepted threat, but in early RA or inception cohorts, growing evidence suggests…
Abstract Number: 780 • 2013 ACR/ARHP Annual Meeting
Serious Infection Rates Among Patients With Systemic Lupus Erythematosus Receiving Corticosteroids and Immunosuppressants
Candace H. Feldman¹, Linda T. Hiraki², Francisco M. Marty³, Wolfgang C. Winkelmayer⁴, Jessica M. Franklin⁵, Daniel H. Solomon^6,7, Seoyoung C. Kim⁸ and Karen H. Costenbader⁹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA, ³Department of Medicine, Division of Infectious Disease, Brigham and Women's Hospital, Boston, MA, ⁴Division of Nephrology, Stanford University School of Medicine, Stanford, CA, ⁵Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ⁶Division of Pharmacoepidemiology, Harvard Medical School, Brigham and Women's Hospital, Division of Rheumatology, Division of Pharmacoepidemiology, Boston, MA, ⁷Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁸Div. of Pharmacoepidemiology and Pharmacoeconomics, Div. of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ⁹Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Infections are among the leading causes of hospitalization and mortality in patients with systemic lupus erythematosus (SLE); approximately 50% have a serious infection during…
Abstract Number: 781 • 2013 ACR/ARHP Annual Meeting
Mortality Rates, Readmissions and Revascularisation Following a First Myocardial Infarction In Patients With Autoimmune Rheumatic Disease Compared With Controls
Sharon Van Doornum^1,2, Megan Bohensky¹, Mark Tacey¹, Caroline Brand^1,3, Vijaya Sundararajan⁴ and Ian Wicks⁵, ¹Melbourne EpiCentre, The University of Melbourne, Melbourne, Australia, ²Rheumatology, The Royal Melbourne Hospital, Melbourne, Australia, ³Melbourne EpiCentre, The Royal Melbourne Hospital, Melbourne, Australia, ⁴Medicine, University of Melbourne, Melbourne, Australia, ⁵Rheumatology Unit, Royal Melbourne Hospital, Melbourne, Australia
Background/Purpose: We have previously demonstrated increased case fatality following myocardial infarction (MI) in rheumatoid arthritis (RA) patients[1], however post-MI case fatality has not been investigated…
Abstract Number: 782 • 2013 ACR/ARHP Annual Meeting
Rates Of Malignancies In Patients From 5 Rheumatoid Arthritis Registries Across The World
Johan Askling¹, Niklas Berglind², Stefan Franzén², Thomas Frisell³, Christopher Garwood⁴, Jeffrey D. Greenberg⁵, Meilien Ho⁶, Marie Holmqvist¹, Laura Horne⁷, Kathy Lampl⁸, Kaleb Michaud⁹, Fredrik Nyberg¹⁰, Dimitrios A. Pappas¹¹, George Reed¹², Eiichi Tanaka¹³, Trung Tran¹⁴, Suzanne Verstappen⁴, Hisashi Yamanaka¹⁵ and Deborah Symmons⁴, ¹Karolinska Institutet, Stockholm, Sweden, ²AstraZeneca R&D Mölndal, Mölndal, Sweden, ³Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ⁵Division of Rheumatology, Department of Medicine, NYU Hospital for Joint Diseases, New York, NY, ⁶AstraZeneca R&D Alderley Park, Macclesfield, United Kingdom, ⁷AstraZeneca, Wilmington, DE, ⁸AstraZeneca R&D Wilmington, Wilmington, DE, ⁹University of Nebraska Medical Center and National Data Bank, Omaha, NE, ¹⁰AstraZeneca R&D, Mölndal, Sweden, ¹¹Columbia University, New York, NY, ¹²University of Massachusetts Medical School, Worcester, MA, ¹³Tokyo Women's Medical University, Tokyo, Japan, ¹⁴MedImmune LLC, Gaithersburg, MD, ¹⁵Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: The overall incidence of cancer in patients with rheumatoid arthritis (RA) is modestly elevated compared with the general population. The extent to which cancer…
Abstract Number: 783 • 2013 ACR/ARHP Annual Meeting
Outcome In Patients With Rheumatoid Disease: Simple Screening Tools Predict Cardiovascular Events and Death
Stefan Kleinert¹, Margret Breunig², Hans-Peter Tony³, Martin Feuchtenberger⁴, Marc Schmalzing⁵, Christian Kneitz⁶, Stefanie Lehmann⁷, Christiane Angermann^7,8, Georg Ertl⁸ and Stefan Störk⁷, ¹Rheumatology/Clinical Immunology,, University Hospital Würzburg, Würzburg, Germany, ²Dept. of Internal Medicine-Cardiology, University Hospital Würzburg, Würzburg, Wuerzburg, Germany, ³Rheumatology/Clinical Immunology, University of Würzburg, Würzburg, Germany, ⁴Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ⁵Rheumatology/Clinical Immunology, University Hospital Würzburg, Würzburg, Germany, ⁶Internal Medicine II, Hospital Südstadt, Rostock, Germany, ⁷Comprehensive Heart Failure Center, University of Würzburg, Würzburg, Germany, ⁸Dept. of Internal Medicine-Cardiology, University Hospital Würzburg, Würzburg, Germany
Background/Purpose: Patients with rheumatoid disease (RD) have an increased mortality risk compared to the normal population, mainly due to cardiovascular (CV) disease. Only a proportion…
Abstract Number: 784 • 2013 ACR/ARHP Annual Meeting
IgG4+ Plasmablasts Are A Novel Biomarker In IgG4-Related Disease
Mollie Carruthers¹, Hamid Mattoo², Zachary S. Wallace³, Vinay Mahajan⁴, Shiv Pillai⁵ and John H. Stone¹, ¹Rheumatology, Massachusetts General Hospital, Boston, MA, ²Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ⁴Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Oncology, Massachusetts General Hospital, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is an immune-mediated disorder that responds to B cell depletion with rituximab (RTX). We detected IgG4+ plasmablasts in the sera of…
Abstract Number: 785 • 2013 ACR/ARHP Annual Meeting
Ophthalmic Manifestations Of IgG4-Related Disease: A Single-Center Experience
Zachary S. Wallace¹, Vikram Deshpande² and John H. Stone³, ¹Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Pathology, Massachusetts General Hospital, Boston, MA, ³Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is an inflammatory disorder responsible for fibrosing, tumefactive lesions that can present in nearly any anatomic location. The orbital manifestations of…
Abstract Number: 786 • 2013 ACR/ARHP Annual Meeting
Antibodies Against Drp-4 and Macropain Subunit C2 As a Potential Marker Of Aosd
Niklas T. Baerlecken¹, Nils Pursche², Torsten Witte³, Reinhold E. Schmidt¹, Marius Hoepfner¹, Frank Moosig⁴, Wolfgang L. Gross⁵, Eugen Feist⁶ and Dirk Foell⁷, ¹Clinical Immunology and Rheumatology, Medical University Hannover, Hannover, Germany, ²Clinical Immunology and Rheumatology, Medical University of Hannover, Hannover, Germany, ³Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, ⁴Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt, Germany, ⁵Dept of Clinical Rheumatology, Medical University at Lubeck, Lubeck, Germany, ⁶Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ⁷Department of Pediatric Rheumatology and Immunology, University of Muenster, Muenster, Germany
Background/Purpose: Making the diagnosis of adult-onset Still's disease (AOSD) is mainly based on the exclusion of inflammatory, infectious and malignant diseases. There are no specific…
Abstract Number: 787 • 2013 ACR/ARHP Annual Meeting
Serum Leucine-Rich Alpha-2 Glycoprotein As a Marker For Disease Activity In Adult-Onset Still’s Disease
You-Jung Ha¹, Jung-Soo Song², Eun-Jin Kang³, Sang-Won Lee⁴, Yong-Beom Park⁴, Soo-Kon Lee⁴ and Sang Tae Choi², ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ²Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, ³Rheumatology, Busan Medical Center, Busan, South Korea, ⁴Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
Background/Purpose: Leucine-rich a2-glycoprotein (LRG) is a plasma protein which contains leucine-rich repeats. Though physiological functions of LRG have not been clarified yet, it has been…
Abstract Number: 767 • 2013 ACR/ARHP Annual Meeting
Zinc Finger Protein ZCCHC6 Is Highly Expressed In Osteoarthritic Cartilage and Regulate The Expression Of Interleukin-6 In Human Chondrocytes
Nahid Akhtar, Ahmad Arida and Tariq M. Haqqi, Anatomy & Neurobiology, North East Ohio Medical University, Rootstown, OH
Background/Purpose: Interleukin-1β (IL-1β) is the major cytokine involved in cartilage catabolism in osteoarthritis(OA) and induces the expression of pro-inflammatory cytokine IL-6. Members of cytoplasmic RNA…
Abstract Number: 748 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Methotrexate For Remission Induction and Maintenance In Granulomatosis With Polyangiitis In Routine Clinical Practice
Megan L. Krause¹, Misbah Baqir², Rodrigo Cartin-Ceba³, Tobias Peikert⁴, Karina Keogh⁴ and Ulrich Specks⁴, ¹Internal Medicine, Mayo Clinic, Rochester, MN, ²Pulmonary/Critical Care, Mayo Clinic, Rochester, MN, ³Pulmonary and Critical Care, Mayo Clinic, Rochester, MN, ⁴Mayo Clinic, Rochester, MN
Background/Purpose: Methotrexate has been shown to be effective for both induction (non-severe disease) and maintenance of remission in patients with Granulomatosis with Polyangiitis (GPA) in…
Abstract Number: 749 • 2013 ACR/ARHP Annual Meeting
High Clinical Remission Rate With Relatively High Incidence Of Serious Infection In Newly-Onset ANCA-Associated Vasculitides In Japan – A Report From The Nationwide Prospective Cohort Study
Masayoshi Harigai¹, Ken-ei Sada², Takao Fujii³, Masahiro Yamamura⁴, Yoshihiro Arimura⁵ and Hirofumi Makino², ¹Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan, ²Department of Medicine and Clinical Science, Okayama University, Okayama, Japan, ³Department of the Control for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, ⁴Center for Rheumatology, Okayama Saiseikai Hospital, Okayama, Japan, ⁵First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan
Background/Purpose: Clinical characteristics and antineutrophil cytoplasmic antibody (ANCA)-serology of ANCA-associated vasculitis (AAV) patients are substantially different between Western and Asian countries. We investigated effectiveness and…
Abstract Number: 750 • 2013 ACR/ARHP Annual Meeting
Maintenance Treatment In Childhood Granulomatosis With Polyangiitis
Marinka Twilt¹, Rayfel Schneider², Diane Hebert³, Elizabeth Harvey³, Ronald M. Laxer², Sharon Dell⁴, Christoph Licht³ and Susanne M. Benseler², ¹Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ²Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Nephrology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Respiratory Medicine, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: Granulomatosis with Polyangiitis (GPA) is a rare but life threatening disease. Most children present with pulmonary bleeds and/or renal failure. Most treatment regimens are…
Abstract Number: 751 • 2013 ACR/ARHP Annual Meeting
Fatigue, Pain, and Functional Disability Among Patients With Vasculitis
Antoine G. Sreih^1,2, Narender Annapureddy³ and Osama Elsallabi⁴, ¹Medicine/Division of Rheumatology, The University of Pennsylvania, Philadelphia, PA, ²Medicine/Rheumatology, Rush University Medical Center, Chicago, IL, ³Rheumatology, Rush University Medical Center, Chicago, IL, ⁴Medicine, Creighton University, Omaha, NE
Background/Purpose: Vasculitis is a heterogeneous group of diseases often resulting in severe morbidity affecting patients’ quality of life. These morbidities are generally attributed to disease…
Abstract Number: 752 • 2013 ACR/ARHP Annual Meeting
Cardiovascular Outcomes Are Worse In Microscopic Polyangiitis Compared To Granulomatosis With Polyangiitis: Data From An Inception Cohort Of Patients With Anti-Neutrophil Cytoplasm Antibody Associated Systemic Vasculitis
Anna Mistry¹, Joanna Robson², Susan L Hogan³, Caroline Poulton³, Yichun Hu⁴, Ronald Falk⁵ and Raashid A. Luqmani⁶, ¹Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Sciences, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ³UNC Kidney Center, Chapel Hill, NC, ⁴UNC Kidney Centre, University of North Carolina, Chapel Hill, North Carolina, Chapel Hill, NC, ⁵Dept of Nephrology and Hypertension, UNC Kidney Center, Chapel Hill, NC, ⁶Rheumatology, Nuffield Orthopaedic Centre, Oxford, United Kingdom
Background/Purpose: A greater than three-fold increase in cardiovascular mortality as been reported within the first five years of diagnosis of anti-neutrophil cytoplasmic antibody (ANCA) associated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].